Memo Therapeutics

Memo Therapeutics, develops MemoMAB a disruptive technology for the mining of human antibodyomes for unbiased discovery of therapeutic antibodies and targets.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Zurich, Switzerland
  • Currency CHF
  • Founded November 2012
  • Employees 2

Company Summary

Memo Therapeutics develops and applies antibody technologies based on its disruptive antibodyome display tool, MemoMAB.
MemoMAB will be commercialized through proprietary target/antibody discovery, technology licensing and services.
Discovery will be funded through services and technology licensing. Therapeutic targets and antibodies will be out-licensed at the pre-IND stage.
Memo Therapeutics is currently seeking to raise seed financing.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free